candesartan and Brain Damage, Chronic studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Brain Damage, Chronic: A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions.

Research Excerpts

Excerpt	Relevance	Reference
"To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke."	7.73	Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006)
"To determine whether BP lowering with candesartan, initiated at reperfusion, can reduce neurovascular damage and improve outcome in a model of hypertension after experimental ischemic stroke."	3.73	Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. ( Ergul, A; Fagan, SC; Hess, DC; Hill, WD; Johnson, MH; Kozak, A; Pollock, DM; Xu, L, 2006)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

candesartan and Brain Damage, Chronic

Research Excerpts

Research

Studies (1)

Authors

Other Studies

Authors	Studies
Fagan, SC	1
Kozak, A	1
Hill, WD	1
Pollock, DM	1
Xu, L	1
Johnson, MH	1
Ergul, A	1
Hess, DC	1